UPDATE: Piper Sandler Downgrades Tabula Rasa Healthcare (TRHC) to Neutral

February 24, 2021 11:50 PM EST
Get Alerts TRHC Hot Sheet
Price: $43.65 -1.33%

Rating Summary:
    10 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 10 | New: 17
Trade Now! 
Join SI Premium – FREE
(Updated - February 25, 2021 4:54 AM EST)

Piper Sandler analyst Sean Wieland downgraded Tabula Rasa Healthcare (NASDAQ: TRHC) from Overweight to Neutral with a price target of $41.00.

The analyst comments "We lack conviction in TRHC's ability to execute on what we believe is an aggressive, and back-half weighted, FY21 guide. We see headwinds to revenue and adjusted EBITDA targets, and can't continue to give the company credit for bookings and pipeline successes when conversions seem to be perpetually delayed. We continue to believe that medication safety will be an important part of managing cost and quality in a healthcare delivery paradigm that's rapidly shifting from fee to value, and view TRHC's end markets as highly attractive, under-penetrated and growing. We remain hopeful that the company can capitalize on being in the right place at the right time, but we downgrade to Neutral pending evidence of execution towards FY21 targets and slightly raise our PT to $41."

For an analyst ratings summary and ratings history on Tabula Rasa Healthcare click here. For more ratings news on Tabula Rasa Healthcare click here.

Shares of Tabula Rasa Healthcare closed at $47.45 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

Sean Wieland